An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer
Kuo T, Cabebe E, Koong A, Norton J, Kunz P, Ford J, Kaiser H, Rogers J, Sikic B, Fisher G. An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer. Journal Of Clinical Oncology 2008, 26: 15571-15571. DOI: 10.1200/jco.2008.26.15_suppl.15571.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply